Owlet announces NYSE acceptance of compliance plan; cure period extended 18 months

Owlet, Inc.

NYSE accepted Owlet's business plan to regain compliance with continued listing standards under Section 802.01B.
Company has 18-month cure period from April 4, 2023 to meet $50M market cap or stockholders' equity threshold.
1-for-14 reverse stock split effective July 7, 2023 to address minimum $1.00 average closing price requirement.
FDA clearance of BabySat medical pulse-oximetry device cited as growth catalyst.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.